Kane Biotech Inc (CVE:KNE) Director Marc Edwards bought 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was bought at an average price of C$0.14 per share, with a total value of C$14,000.00. Following the completion of the acquisition, the director now owns 1,846,000 shares of the company’s stock, valued at approximately C$258,440.
CVE:KNE traded up C$0.00 during midday trading on Tuesday, reaching C$0.15. The company had a trading volume of 29,300 shares, compared to its average volume of 68,581. The firm has a market cap of $11.22 million and a price-to-earnings ratio of -3.82. The business’s fifty day simple moving average is C$0.13. Kane Biotech Inc has a 12-month low of C$0.06 and a 12-month high of C$0.15. The company has a debt-to-equity ratio of 187.91, a current ratio of 0.24 and a quick ratio of 0.12.
Kane Biotech (CVE:KNE) last announced its quarterly earnings results on Wednesday, May 22nd. The company reported C($0.01) earnings per share (EPS) for the quarter. The business had revenue of C$0.62 million during the quarter.
Kane Biotech Inc, a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoo for dogs, cats, and horses under the Alosera trademark.
Featured Article: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.